Ascletis Pharma Inc. (FRA:2VJ)

Market Cap	2.04B +324.1%
Revenue (ttm)	280.99K -76.6%
Net Income	-30.73M
EPS	-0.03
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	100
Open	1.860
Previous Close	1.760
Day's Range	1.850 - 1.860
52-Week Range	0.505 - 1.960
Beta	n/a
RSI	69.02
Earnings Date	Mar 26, 2026

About Ascletis Pharma

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of prima...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2013
• Employees: 208
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 2VJ

Financial Performance

In 2024, Ascletis Pharma's revenue was 1.28 million, a decrease of -97.73% compared to the previous year's 56.60 million. Losses were -300.94 million, 108.0% more than in 2023.

Financial numbers in CNY